Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism

References

• United Nations Department of Economic and Social Affairs Population Division. World contraceptive use 2007. Accessed 5 August 2009 from: http://www.un.org/esa/population/publications/contraceptive2007/contraceptive_2007_table.pdf
   Google Scholar
• Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: A randomized trial of 20 micrograms and 35 micrograms estrogen preparations. Contraception 1999;60:321–9.
   PubMed Web of Science ®Google Scholar
• Farley TM, Collins J, Schlesselman JJ. Hormonal contraception and risk of cardiovascular disease. An international perspective. Contraception 1998;57:211–30.
   PubMed Web of Science ®Google Scholar
• Blackburn RD, Cunkelman JA, Zlidar VM. Oral contraceptives – an update. In Population Reports, Series A, No. 9, 2000.
   Google Scholar
• Szarewski A, Mansour D, Shulman LP. 50 years of ‘The Pill’: Celebrating a golden anniversary. J Fam Plann Reprod Health Care 2010;36:231–8.
   PubMed Web of Science ®Google Scholar
• Lidegaard Ø, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: National follow-up study. BMJ 2009;339:b2890.
   PubMed Web of Science ®Google Scholar
• van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, . The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: Results of the MEGA case-control study. BMJ 2009;339:b2921.
   PubMed Web of Science ®Google Scholar
• Reid RL, Westhoff C, Mansour D, . Oral contraceptives and venous thromboembolism consensus opinion from an international workshop held in Berlin, Germany in December 2009. J Fam Plann Reprod Health Care 2010;36:117–22.
   PubMed Web of Science ®Google Scholar
• Shapiro S, Dinger J. Risk of venous thromboembolism among users of oral contraceptives: A review of two recently published studies. J Fam Plann Reprod Health Care 2010;36:33–8.
   PubMed Web of Science ®Google Scholar
• Suissa S, Spitzer WO, Rainville B, . Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. Hum Reprod 2000;15:817–21.
   PubMed Web of Science ®Google Scholar
• Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: Final results from the European active surveillance study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007;75:344–54.
   PubMed Web of Science ®Google Scholar
• Hoffmann H, Moore C, Zimmermann H, . Approaches to the replacement of ethinylestradiol by natural 17beta-estradiol in combined oral contraceptives. Exp Toxicol Pathol 1998;50:458–64.
   PubMed Web of Science ®Google Scholar
• Lello S. Nomegestrol acetate: Pharmacology, safety profile and therapeutic efficacy. Drugs 2010;70:541–59.
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006;12:169–78.
   PubMed Web of Science ®Google Scholar
• Duijkers IJ, Klipping C, Grob P, Korver T. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol. Eur J Contracept Reprod Health Care 2010;15: 314–25.
   PubMed Web of Science ®Google Scholar
• Christin-Maitre S, Serfaty D, Chabbert-Buffet N, . Comparison of a 24-day and a 21-day pill regimen for the novel combined oral contraceptive, nomegestrol acetate and 17β-estradiol (NOMAC/E2): A double-blind, randomized study. Hum Reprod 2011;26:1338–47.
   PubMed Web of Science ®Google Scholar
• Ågren UM, Anttila M, Mäenpää-Liukko K, . Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17b-oestradiol in comparison to one containing levonorgestrel and ethinylestradiol on markers of endocrine function. Eur J Contracept Reprod Health Care 2011;16:458–468.
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use. Guideline on clinical investigation of steroid contraceptives in women. In EMEA/CPMP/EWP/519/98 Rev 1, 2005.
   Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.
   PubMed Web of Science ®Google Scholar
• Gerstman BB, Piper JM, Tomita DK, . Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991;133:32–7.
   PubMed Web of Science ®Google Scholar
• Lidegaard Ø, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism: A five-year national case-control study. Contraception 2002;65:187–96.
   PubMed Web of Science ®Google Scholar
• Jick H, Jick SS, Gurewich V, . Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589–93.
   PubMed Web of Science ®Google Scholar
• Spitzer WO, Lewis MA, Heinemann LA, . Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study. Transnational research group on oral contraceptives and the health of young women. BMJ 1996;312:83–8.
   PubMed Web of Science ®Google Scholar
• Herings RM, Urquhart J, Leufkens HG. Venous thromboembolism among new users of different oral contraceptives. Lancet 1999;354:127–8.
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: A meta-analysis. J Clin Endocrinol Metab 2005;90:3863–70.
   PubMed Web of Science ®Google Scholar
• Lidegaard Ø, Kreiner S. Contraceptives and cerebral thrombosis: A five-year national case-control study. Contraception 2002;65:197–205.
   PubMed Web of Science ®Google Scholar
• Lindberg UB, Crona N, Stigendal L, . A comparison between effects of estradiol valerate and low dose ethinyl estradiol on haemostasis parameters. Thromb Haemost 1989;61:65–9.
   PubMed Web of Science ®Google Scholar
• Mashchak CA, Lobo RA, Dozono-Takano R, . Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 1982;144:511–8.
   PubMed Web of Science ®Google Scholar
• Parke S, Nahum G, Mellinger U, Junge W. Metabolic effects of a new four-phasic oral contraceptive containing estradiol valerate and dienogest. Obstet Gynecol 2008;111(4 Suppl.):12S–13S.
   Web of Science ®Google Scholar
• Gaussem P, Alhenc-Gelas M, Thomas JL, . Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17beta-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study. Thromb Haemost 2011;105:560–7.
   PubMed Web of Science ®Google Scholar
• Rosing J, Tans G, Nicolaes GA, . Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997;97:233–8.
   PubMed Web of Science ®Google Scholar
• Kemmeren JM, Algra A, Meijers JCM, . Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: A randomized trial. Blood 2004;103:927–33.
   PubMed Web of Science ®Google Scholar
• Conard J. Biological coagulation findings in third-generation oral contraceptives. Hum Reprod Update 1999; 5:672–80.
   PubMed Web of Science ®Google Scholar
• Tans G, Curvers J, Middeldorp S, . A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000;84:15−21.
   PubMed Web of Science ®Google Scholar
• de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999;93:1271−6.
   PubMed Web of Science ®Google Scholar
• Tans G, van Hylckama Vlieg A, Thomassen MC, . Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 2003;122:465−70.
   PubMed Web of Science ®Google Scholar
• Godsland IF, Winkler U, Lidegaard Ø, Crook D. Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms. Drugs 2000;60:721−869.
   PubMed Web of Science ®Google Scholar
• Godsland IF. Biology: Risk factor modification by OCs and HRT lipids and lipoproteins. Maturitas 2004;47: 299−303.
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. Pharmacology of different progestogens: The special case of drospirenone. Climacteric 2005;8 (Suppl. 3):4−12.
   PubMed Web of Science ®Google Scholar
• Endrikat J, Klipping C, Cronin M, . An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. Contraception 2002;65:215–21.
   PubMed Web of Science ®Google Scholar
• Scharnagl H, Petersen G, Nauck M, . Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 microg or 30 microg) and levonorgestrel (100 microg or 150 microg) on lipoprotein metabolism. Contraception 2004;69:105–13.
   PubMed Web of Science ®Google Scholar
• Skouby SO, Endrikat J, Düsterberg B, . A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel. Contraception 2005;71: 111–7.
   PubMed Web of Science ®Google Scholar
• Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: Effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev 2009:CD006133.
   Web of Science ®Google Scholar
• Brussaard HE, Gevers Leuven JA, Frölich M, . Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia 1997;40: 843–9.
   PubMed Web of Science ®Google Scholar
• Brown MD, Korytkowski MT, Zmuda JM, . Insulin sensitivity in postmenopausal women: Independent and combined associations with hormone replacement, cardiovascular fitness, and body composition. Diabetes Care 2000;23:1731–6.
   PubMed Web of Science ®Google Scholar
• Ryan AS, Nicklas BJ, Berman DM. Hormone replacement therapy, insulin sensitivity, and abdominal obesity in postmenopausal women. Diabetes Care 2002;25: 127–33.
   PubMed Web of Science ®Google Scholar
• Howard BV, Hsia J, Ouyang P, . Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose tolerance. Circulation 2004;110:201–6.
   PubMed Web of Science ®Google Scholar
• Os I, Os A, Abdelnoor M, . Insulin sensitivity in women with coronary heart disease during hormone replacement therapy. J Womens Health (Larchmt) 2005;14:137–45.
   PubMed Web of Science ®Google Scholar
• Bonds DE, Lasser N, Qi L, . The effect of conjugated equine oestrogen on diabetes incidence: The women's health initiative randomised trial. Diabetologia 2006;49: 459–68.
   PubMed Web of Science ®Google Scholar
• Shadoan MK, Kavanagh K, Zhang L, . Addition of medroxyprogesterone acetate to conjugated equine estrogens results in insulin resistance in adipose tissue. Metabolism 2007;56:830–7.
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. Progestins and cardiovascular risk markers. Steroids 2000;65:651–8.
   PubMed Web of Science ®Google Scholar
• Cushman M, Arnold AM, Psaty BM, . C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: The cardiovascular health study. Circulation 2005;112:25–31.
   PubMed Web of Science ®Google Scholar
• van Rooijen M, Hansson LO, Frostegård J, . Treatment with combined oral contraceptives induces a rise in serum C-reactive protein in the absence of a general inflammatory response. J Thromb Haemost 2006;4:77–82.
   PubMed Web of Science ®Google Scholar
• White T, Özel B, Jain JK, Stanczyk FZ. Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins. Contraception 2006;74:293–6.
   PubMed Web of Science ®Google Scholar
• Johnson JV, Lowell J, Badger GJ, . Effects of oral and transdermal hormonal contraception on vascular risk markers: A randomized controlled trial. Obstet Gynecol 2008;111:278–84.
   PubMed Web of Science ®Google Scholar
• Ridker PM, MacFadyen JG, Fonseca FA, . Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: Justification for the use of statins in prevention: An intervention trial evaluating rosuvastatin (JUPITER). Circ Cardiovasc Qual Outcomes 2009;2:616–23.
   PubMed Web of Science ®Google Scholar
• Odlind V, Milsom I, Persson I, Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand 2002;81:482–90.
   PubMed Web of Science ®Google Scholar
• Oral Contraceptive and Hemostasis Study Group. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: Conclusions from a large randomized multicenter study. Contraception 2003;67: 173–85.
   PubMed Web of Science ®Google Scholar
• Kluft C, Endrikat J, Mulder SM, . A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol. Contraception 2006;73:336–43.
   PubMed Web of Science ®Google Scholar